The new Clinical Conductor continues to provide additional features and functionality that make the application cleaner, more intuitive and even more adaptable to our needs.
Past News ReleasesRSS
Rochester, NY (PRWEB) April 02, 2014
The new Clinical Conductor CTMS is here, and with it comes a revolution in clinical trial collaboration. The industry’s only true collaborative CTMS takes this capability to a new level. The leading financial capabilities of Clinical Conductor have also been strengthened in this release and provide users enhanced levels of clarity and granularity of their trial finances, allowing them to maximize profitability and more easily ensure billing compliance.
Clinical Conductor provides research organizations with collaborative CTMS functionality that is now capable of elevating every facet of clinical research to the next level by bringing all research components and partners together in real time. The collaborative qualities of Clinical Conductor are enhanced by the application’s new CTMS configurations. Now, sites, site networks, CROs and health systems will be fitted with a CTMS that contains the exact features and functionally required by their roles and responsibilities in clinical research.
“We are very proud to have been the first CTMS to provide the marketplace with the collaborative and financial functionality demanded by its users. This release further revolutionizes the way that’s done,” said Jeffrey Markin, VP and COO at Bio-Optronics. “For example, whether the user is deploying a protocol centrally to multiple clinical sites conducting the study or aggregating study events and associated financial details, the new Clinical Conductor is designed to provide them with the proper tools to successfully navigate the increasing complexities and regulations of the clinical research industry.”
The new Clinical Conductor has also been fitted with important financial enhancements. These additions give users the granularity they need to capture all possible revenues and improve their business processes over time. What’s more, this granularity will help organizations adhere to GCP guidelines and ensure accurate billing compliance is achieved. Specific additions have also been made that address the complexity of attributing payments and receivables to the proper sources in the complex clinical research and routine care environment. The financial functionality found in Clinical Conductor continues to make it possible for users to achieve maximum profitability while simultaneously conducting the highest quality research possible.
Kimber Breeden, a Financial Consultant at Benchmark Research stated, “The new Clinical Conductor continues to provide additional features and functionality that make the application cleaner, more intuitive and even more adaptable to our needs. These additions make it easy for our organization to manage and execute the highest quality clinical research possible.”
Continuing to focus on industry-leading customer service, the new Clinical Conductor contains many features that are derived directly from the feedback of Clinical Conductor users. These updates aid in increasing the application’s functionality and ease-of-use. The Clinical Conductor team takes pride in developing close relationships with Clinical Conductor users and utilizing these relationships to ensure the CTMS is always meeting the changing needs of users around the world.
About Clinical Conductor CTMS
Clinical Conductor is the industry’s first collaborative and configurable CTMS for organizations managing or executing clinical trials. Created by Bio-Optronics, an industry-leading provider of software and services to healthcare and life sciences organizations around the world, Clinical Conductor is designed to provide users with the specific features and functionality they need to effectively collaborate with or among sites and other partners, deliver high-quality research and attain maximum profitability. Used by over 1,700 organizations around the world, Clinical Conductor provides organizations with the tools they need to continue to raise the bar in clinical research.